{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"groups":[{"description":"Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.","id":"OG000","title":"Group 1 (Avelumab and MHC Class I Up-regulation)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients were evaluated for aGvHD greater than or equal to Grade 3","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Count of Participants Who Experienced Grade III-IV Acute Graft-versus-host Disease (GVHD) (Arm I)","type":"PRIMARY","unitOfMeasure":"Participants"}